Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 299

1.

Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.

Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T.

Clin Chem Lab Med. 2011 Oct;49(10):1721-6. doi: 10.1515/CCLM.2011.242. Epub 2011 Jun 22.

PMID:
21692685
[PubMed - indexed for MEDLINE]
2.

Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.

Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J.

Ann Thorac Surg. 2008 Jan;85(1):265-72; discussion 272.

PMID:
18154821
[PubMed - indexed for MEDLINE]
3.

Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma.

Murakami A, Tabata C, Tabata R, Okuwa H, Nakano T.

Oncol Lett. 2012 Mar;3(3):581-585. Epub 2011 Dec 23.

PMID:
22740956
[PubMed]
Free PMC Article
4.

Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.

Canessa PA, Franceschini MC, Ferro P, Battolla E, Dessanti P, Manta C, Sivori M, Pezzi R, Fontana V, Fedeli F, Pistillo MP, Roncella S.

Cancer Invest. 2013 Jan;31(1):43-50. doi: 10.3109/07357907.2012.749265. Epub 2012 Dec 18.

PMID:
23249166
[PubMed - indexed for MEDLINE]
5.

Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.

Hirayama N, Tabata C, Tabata R, Maeda R, Yasumitsu A, Yamada S, Kuribayashi K, Fukuoka K, Nakano T.

Respir Med. 2011 Jan;105(1):137-42. doi: 10.1016/j.rmed.2010.10.010. Epub 2010 Oct 30.

PMID:
21041073
[PubMed - indexed for MEDLINE]
Free Article
6.

Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.

Ferro P, Canessa PA, Battolla E, Dessanti P, Franceschini MC, Chiaffi L, Morabito A, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S.

Anticancer Res. 2013 Jun;33(6):2707-13.

PMID:
23749930
[PubMed - indexed for MEDLINE]
7.

Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.

Creaney J, Dick IM, Segal A, Musk AW, Robinson BW.

Lung Cancer. 2013 Dec;82(3):491-8. doi: 10.1016/j.lungcan.2013.09.016. Epub 2013 Oct 9.

PMID:
24161718
[PubMed - indexed for MEDLINE]
8.

Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.

Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T.

J Thorac Oncol. 2008 Nov;3(11):1317-24. doi: 10.1097/JTO.0b013e318187491c.

PMID:
18978568
[PubMed - indexed for MEDLINE]
9.

Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.

Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P.

Clin Cancer Res. 2007 May 15;13(10):2928-35.

PMID:
17504993
[PubMed - indexed for MEDLINE]
Free Article
10.

Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.

Muley T, Dienemann H, Herth FJ, Thomas M, Meister M, Schneider J.

J Thorac Oncol. 2013 Jul;8(7):947-51. doi: 10.1097/JTO.0b013e31828f696b.

PMID:
23777840
[PubMed - indexed for MEDLINE]
11.

Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.

Grigoriu B, Chahine B, Zerimech F, Grégoire M, Balduyck M, Copin MC, Devos P, Lassalle P, Scherpereel A.

Clin Biochem. 2009 Jul;42(10-11):1046-50. doi: 10.1016/j.clinbiochem.2009.03.007. Epub 2009 Mar 18.

PMID:
19302997
[PubMed - indexed for MEDLINE]
12.

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, Segal A, Musk AW, Lee YC, Skates SJ, Nowak AK, Robinson BW.

Thorax. 2014 Oct;69(10):895-902. doi: 10.1136/thoraxjnl-2014-205205. Epub 2014 Jul 18.

PMID:
25037982
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions.

Alemán C, Manuel Porcel J, Ma Segura R, Alegre J, Esquerda A, Ruiz E, Bielsa S, de Sevilla TF.

Med Clin (Barc). 2009 Oct 3;133(12):449-53. doi: 10.1016/j.medcli.2008.11.047. Epub 2009 Sep 24.

PMID:
19783262
[PubMed - indexed for MEDLINE]
14.

Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.

Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, León Jiménez A, Isidro Montes I, Cebollero Rivas P.

Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):646-50. doi: 10.1158/1055-9965.EPI-08-0422. Epub 2009 Feb 3.

PMID:
19190155
[PubMed - indexed for MEDLINE]
Free Article
15.

Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.

Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, Terada T, Iida S, Tamura K, Fukuoka K, Kuribayashi K, Nakano T.

J Thorac Oncol. 2010 Apr;5(4):479-83. doi: 10.1097/JTO.0b013e3181d2f008.

PMID:
20357617
[PubMed - indexed for MEDLINE]
16.

Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion.

Tsuji S, Tsuura Y, Morohoshi T, Shinohara T, Oshita F, Yamada K, Kameda Y, Ohtsu T, Nakamura Y, Miyagi Y.

Br J Cancer. 2010 Aug 10;103(4):517-23. doi: 10.1038/sj.bjc.6605786. Epub 2010 Jul 13.

PMID:
20628387
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.

Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, Horick N, Skates SJ, Robinson BW.

Thorax. 2007 Jul;62(7):569-76. Epub 2007 Mar 13.

PMID:
17356060
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Clinical utility of 18-fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma.

Terada T, Tabata C, Tabata R, Okuwa H, Kanemura S, Shibata E, Nakano T.

Exp Ther Med. 2012 Aug;4(2):197-200. Epub 2012 May 11.

PMID:
23139709
[PubMed]
Free PMC Article
19.

[Exploratory study on the detection of markers for diagnosing early-stage malignant mesothelioma].

Fukuoka K, Tanaka F, Tsujimura T, Hashimoto-Tamaoki T, Hasegawa S, Nakano T.

Nihon Eiseigaku Zasshi. 2011 May;66(3):553-7. Japanese.

PMID:
21701086
[PubMed - indexed for MEDLINE]
Free Article
20.

Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.

Iwahori K, Osaki T, Serada S, Fujimoto M, Suzuki H, Kishi Y, Yokoyama A, Hamada H, Fujii Y, Yamaguchi K, Hirashima T, Matsui K, Tachibana I, Nakamura Y, Kawase I, Naka T.

Lung Cancer. 2008 Oct;62(1):45-54. doi: 10.1016/j.lungcan.2008.02.012. Epub 2008 Apr 3.

PMID:
18394747
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk